192 related articles for article (PubMed ID: 10813207)
1. Progressive systemic sclerosis and the lung.
Veeraraghavan S; Sharma OP
Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
[TBL] [Abstract][Full Text] [Related]
2. Scleroderma lung disease.
Solomon JJ; Olson AL; Fischer A; Bull T; Brown KK; Raghu G
Eur Respir Rev; 2013 Mar; 22(127):6-19. PubMed ID: 23457159
[No Abstract] [Full Text] [Related]
3. Interstitial lung disease in systemic sclerosis: pathophysiology, current and new advances in therapy.
Jain S; Shahane A; Derk CT
Inflamm Allergy Drug Targets; 2012 Aug; 11(4):266-77. PubMed ID: 22506881
[TBL] [Abstract][Full Text] [Related]
4. Imaging lung disease in systemic sclerosis.
Strollo D; Goldin J
Curr Rheumatol Rep; 2010 Apr; 12(2):156-61. PubMed ID: 20425026
[TBL] [Abstract][Full Text] [Related]
5. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
Mangat P; Conron M; Gabbay E; Proudman SM;
Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
[TBL] [Abstract][Full Text] [Related]
6. [Systemic sclerosis].
Schinke S; Riemekasten G
Internist (Berl); 2019 Dec; 60(12):1251-1269. PubMed ID: 31754753
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of isolated DLCO reduction in systemic sclerosis patients without cardio-pulmonary involvement at baseline.
Colaci M; Giuggioli D; Sebastiani M; Manfredi A; Lumetti F; Luppi F; Cerri S; Ferri C
Reumatismo; 2015 Dec; 67(4):149-55. PubMed ID: 27215180
[TBL] [Abstract][Full Text] [Related]
8. New therapeutic strategies in the management of systemic sclerosis.
Allanore Y; Avouac J; Wipff J; Kahan A
Expert Opin Pharmacother; 2007 Apr; 8(5):607-15. PubMed ID: 17376016
[TBL] [Abstract][Full Text] [Related]
9. The lung in systemic sclerosis.
Steen VD
J Clin Rheumatol; 2005 Feb; 11(1):40-6. PubMed ID: 16357695
[No Abstract] [Full Text] [Related]
10. Circulating endothelin-1 levels in systemic sclerosis subsets--a marker of fibrosis or vascular dysfunction?
Morelli S; Ferri C
J Rheumatol; 1996 Apr; 23(4):789-91. PubMed ID: 8730152
[No Abstract] [Full Text] [Related]
11. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Mathai SC; Hummers LK; Champion HC; Wigley FM; Zaiman A; Hassoun PM; Girgis RE
Arthritis Rheum; 2009 Feb; 60(2):569-77. PubMed ID: 19180517
[TBL] [Abstract][Full Text] [Related]
12. Emerging drugs and therapeutics for systemic sclerosis.
Lee JJ; Pope JE
Expert Opin Emerg Drugs; 2016 Dec; 21(4):421-430. PubMed ID: 27813423
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary complications: one of the most challenging complications of systemic sclerosis.
Wells AU; Steen V; Valentini G
Rheumatology (Oxford); 2009 Jun; 48 Suppl 3():iii40-4. PubMed ID: 19487223
[TBL] [Abstract][Full Text] [Related]
14. Interstitial lung disease in systemic sclerosis: current and future treatment.
Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
[TBL] [Abstract][Full Text] [Related]
15. Systemic sclerosis sine scleroderma presenting as pulmonary intersticial fibrosis.
Vañó Sanchis D; Arranz Garcia G; Yglesias PJ
Clin Rheumatol; 2006 May; 25(3):382-3. PubMed ID: 16211337
[No Abstract] [Full Text] [Related]
16. The role of vasodilators in patients with progressive systemic sclerosis. Interstitial lung disease and pulmonary hypertension.
Ohar J; Polatty C; Robichaud A; Fowler A; Vetrovec G; Glauser F
Chest; 1985 Oct; 88(4 Suppl):263S-265S. PubMed ID: 4042734
[TBL] [Abstract][Full Text] [Related]
17. Factors relating to impaired stroke volume during the 6-minute walk test in patients with systemic sclerosis.
Someya F; Mugii N; Oohata S
Clin Exp Rheumatol; 2016; 34 Suppl 100(5):152-156. PubMed ID: 27463117
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
Broad K; Pope JE
Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
[TBL] [Abstract][Full Text] [Related]
19. Assessment and management of scleroderma lung disease.
Bolster MB; Silver RM
Curr Opin Rheumatol; 1999 Nov; 11(6):508-13. PubMed ID: 10551676
[TBL] [Abstract][Full Text] [Related]
20. Association of gastroesophageal factors and worsening of forced vital capacity in systemic sclerosis.
Zhang XJ; Bonner A; Hudson M; ; Baron M; Pope J
J Rheumatol; 2013 Jun; 40(6):850-8. PubMed ID: 23547215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
